Bone marrow-derived mesenchymal stem cells (MSCs) are capable of migrating and homing to brain tumors in vivo and therefore is a promising targeted-delivery vehicle in cancer gene therapy. MSCs are transfected or transducted with the therapeutic genes and achieve stable expression in vitro, then are delivered to the host to exert their therapeutic effects. The Ex Vivo gene transfer of MSCs has been studied in several types of tumors including gliomas, and results were postive. The safety of MSC-based gene delivery remains to be controversial. The interactions between MSCs and host tumor cells need to be investigated.

Follicular lymphoma (FL) is a kind of indolent non-Hodgkin lymphoma (iNHL), which origins from follicle germinal center. Multiple researches reported the latest development about treatment of FL in the 58th American Society of Hematology (ASH) Annual Meeting. The outcomes of clinical trials in which GAl01 combined with chemotherapy and bendamustine in combination with 90Y-ibritumomab tiuxetan for the advanced stage FL were exciting. Relapsed/refractory FL patients who receive tandem autologous followed by nonmyeloablative allogeneic transplantation could acquire preferable remissions. With the emerging of novel drugs including inhibitor of bcl-2 or PI3K and antibody drug conjugate, more and more improvements of efficacy and remission were made in the treatment of relapsed/refractory FL therapy and remission.

Positron emission tomography-computed tomography (PET-CT) with both anatomic and functional information is now widely utilized for most lymphoma subtypes,among which,the pretreatment staging and response assessment of PET-CT in Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL)have been well documented.Multiple clinical trials are ongoing using PET-CT for therapy monitoring.Additionally,factors interpreting interim PET (PET-i) like visual analysis using Deauville 5-PS,metabolic tumor volume at baseline (MTV0),and △ SUVmaxPET0-i show different prognostic values.However,the management of PET-CT in lymphoma is still elusive,further trials remain to be done to get evidences for the use of PET-CT in guiding therapeutic decisions.

TWO average expense control(TAEC) is the method that the hospital want to control the increasing breadth of medicine expense by limiting the total expense which include both clinic expense and hospitalize expense.TAEC will fake great help to improve the relationship of docfor and patient and to promote the hospital work.But the method of TAEC will also to be optimize further.

Chronic lymphocytic leukemia (CLL) is a chronic B-cell lymphoproliferative clonal disease with a highly heterogeneous clinical course. In recent years, with the emerging of immunochemotherapy, bcl-2 inhibitor, B-cell receptor signal transduction kinase inhibitors and the chimeric antigen receptor-T cell (CAR-T), more and more improvements were made in CLL therapy and remission. This report addressed the progress of CLL therapy in the 57th American Society of Hematology annual meeting.

The role of consolidating radiation therapy (RT) is very controversial in Hodgkin lymphoma (HL),especially in adolescents and young adults (AYA) HL.The key problem is how to achieve better therapeutic effect but bear less toxicities in chemotherapy and radiotherapy,which will be hopefully solved by clinical trials adopting interim positron emission tomography (iPET) scanning to guide therapy for HL.The new technologies including whole genome amplification (WGA),high-throughput gene sequencing (NGS) assay and genome-wide association study (GWAS) further illustrate abnormal signaling pathways in HL,such as NF-κB,JAK/STAT and PI3K pathway,which may provide new therapeutic targets for the disease.

Lenalidomide is an oral immunomodulator with multiple functions including immune regulation, anti-tumor, and regulation of tumor microenvironment. Since the United States Food and Drug Administration (FDA) approved lenalidomide for the treatment of mantle cell lymphoma, recent studies have indicated that lenalidomide monotherapy or lenalidomide combinations in other types of lymphoma also has broad prospects. The treatment progress of lenalidomide in lymphoma will be summarized in this paper based on the new reports in the 57th American Society of Hematology (ASH) annual meeting.

With the recent success of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, and the phosphoinositide-3-kinase (PI3K) inhibitor idelalisib in the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL), a number of new agents targeting the B cell receptor (BCR) pathway are in clinical development. In the 57th American Society of Hematology (ASH) annual meeting, great interests are still focused on these two drugs, either monotherapy or combination in the treatment of CLL. On the other hand, SYK inhibitors, new BTK and PI3K antagonists are also coming to the forefront, casting a new light on the treatment of ibrutinib/idelalisb-resistant patients. The progresses of BCR pathway inhibitors in CLL will be summarized in this paper based on the reports in the 57th ASH annual meeting.

Chronic lymphocytic leukemia (CLL) is a kind of malignant B-cell chronic lymphoproliferative disorder with highly heterogeneous clinical courses. Due to the recent advances in immunology, cellular genetics and molecular biology, several prognostic markers based on genetic, phenotypic, and molecular biology characteristics of CLL cells have emerged in the past decade. This article reviews the reports from the 57th American Society of Hematology (ASH) annual meeting on the progress of the prognosis of CLL.

Objective To assess the value of multislice spiral computed tomography (MSCT) in diagnosing pulmonary hypertension.Methods One hundred and forty-two patients on hemodialysis were divided into the group with pulmonary artery hypertension and the group without pulmonary artery hypertension.The diagnosis of pulmonary artery hypertension (pulmonary artery systolic pressure,PASP ＞ 35 mmHg) was according to the guideline from the American Society of Echocardiography.All patients were received the check of MSCT and the diameters of the main pulmonary artery,ascending aorta and descending aorta were recorded.PASP and left ventricular ejection fraction were assessed by echocardiography.High sensitivity C-reactive protein and rumor necrosis factor were measured by automatic analyzer and enzyme linked immunosorbent assay.Results There were significant differences between the two groups in systolic blood pressure,hemoglobin,serum albumin,high sensitivity C-reactive protein and TNF-α (P ＜ 0.05); There were significant differences between the two groups in diameters of the maim pulmonary artery,ratio of the diameter of the main pulmonary artery to the diameter of ascending aorta and ratio of the diameter of the main pulmonary artery to the diameter of descending aorta (P ＜ 0.05).In different heart function groups,there were significant differences in diameters of the main pulmonary artery,ratio of the diameter of the main pulmonary artery to the diameter of ascending aorta,and ratio of the diameter of the main pulmonary artery to the diameter of descending aorta,and left ventricular ejection fraction (P ＜ 0.05).Ratio of the diameter of the maim pulmonary artery to the diameter of ascending aorta was positively related to PASP (r=48.77,P ＜ 0.01),and left ventricular ejection fraction was negatively related to PASP (r=-0.40,P ＜ 0.01).In multivariate linear regression,TNF-α,ratio of the diameter of the maim pulmonary artery to the diameter of ascending aorta and ejection fraction were independent factors of PASP (P ＜ 0.01).Conclusions MSCT measurements play an important role in diagnosis of pulmonary hypertension and in evaluation of clinical prognosis in patients on hemodialysis.